Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rahul Aggarwal

Showing results (161-170 of 223) with videos related to

Pageof 23
Sort By:
Magnetic Resonance in Medicine|October 31, 2018
Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patientsJeremy W Gordon, Hsin-Yu Chen, Adam Autry, et al.
Molecular Cancer Research : MCR|June 9, 2017
Real-Time Transferrin-Based PET Detects MYC-Positive Prostate CancerRahul Aggarwal, Spencer C Behr, Pamela L Paris, et al.
Theranostics|February 23, 2024
Development of CD46 targeted alpha theranostics in prostate cancer using <sup>134</sup>Ce/<sup>225</sup>Ac-Macropa-PEG<sub>4</sub>-YS5Kondapa Naidu Bobba, Anil P Bidkar, Anju Wadhwa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2025
Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 StudyRahul Aggarwal, Sylvie Rottey, Alice Bernard-Tessier, et al.
Urologic Oncology|November 18, 2019
Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working groupVivek Narayan, Michael Harrison, Heather Cheng, et al.
ACS Chemical Biology|April 8, 2020
A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission TomographyYangjie Huang, Ning Zhao, Yung-Hua Wang, et al.
The Lancet. Oncology|November 3, 2023
Single-dose <sup>177</sup>Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trialRahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, et al.
Urologic Oncology|July 26, 2021
A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II studyYaoYao Pollock, Li Zhang, Stacey A Kenfield, et al.
JCO Precision Oncology|July 12, 2021
Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion SequencingEmmalyn Chen, Clinton L Cario, Lancelote Leong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor MalignanciesPamela Munster, Rahul Aggarwal, David Hong, et al.
Pageof 23

Showing results (161-170 of 223) with videos related to

Sort By:
Pageof 23
Magnetic Resonance in Medicine|October 31, 2018
Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patientsJeremy W Gordon, Hsin-Yu Chen, Adam Autry, et al.
Molecular Cancer Research : MCR|June 9, 2017
Real-Time Transferrin-Based PET Detects MYC-Positive Prostate CancerRahul Aggarwal, Spencer C Behr, Pamela L Paris, et al.
Theranostics|February 23, 2024
Development of CD46 targeted alpha theranostics in prostate cancer using <sup>134</sup>Ce/<sup>225</sup>Ac-Macropa-PEG<sub>4</sub>-YS5Kondapa Naidu Bobba, Anil P Bidkar, Anju Wadhwa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2025
Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 StudyRahul Aggarwal, Sylvie Rottey, Alice Bernard-Tessier, et al.
Urologic Oncology|November 18, 2019
Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working groupVivek Narayan, Michael Harrison, Heather Cheng, et al.
ACS Chemical Biology|April 8, 2020
A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission TomographyYangjie Huang, Ning Zhao, Yung-Hua Wang, et al.
The Lancet. Oncology|November 3, 2023
Single-dose <sup>177</sup>Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trialRahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, et al.
Urologic Oncology|July 26, 2021
A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II studyYaoYao Pollock, Li Zhang, Stacey A Kenfield, et al.
JCO Precision Oncology|July 12, 2021
Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion SequencingEmmalyn Chen, Clinton L Cario, Lancelote Leong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor MalignanciesPamela Munster, Rahul Aggarwal, David Hong, et al.
Pageof 23